EdgarLookup

INTEL CORP — Financial Data

Annual figures from SEC EDGAR XBRL filings (10-K)

These figures are extracted directly from XBRL-tagged financial statements that INTEL CORP filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.

Overview All Filings Annual Quarterly Insiders
-0.5%
Profit Margin
Net income ÷ revenue
-0.1%
Return on Assets
Net income ÷ assets
-0.5%
Revenue Growth
Year over year

Revenue

Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.

Fiscal Year Period End Value Filed
FY2025 Dec 27, 2025 $52.85B Jan 23, 2026
FY2025 Dec 28, 2024 $53.10B Jan 23, 2026
FY2025 Dec 30, 2023 $54.23B Jan 23, 2026
FY2024 Dec 31, 2022 $63.05B Jan 31, 2025
FY2023 Dec 25, 2021 $79.02B Jan 26, 2024
FY2022 Dec 26, 2020 $77.87B Jan 27, 2023
FY2021 Dec 28, 2019 $71.97B Jan 27, 2022
FY2020 Dec 29, 2018 $70.85B Jan 22, 2021
FY2019 Dec 30, 2017 $62.76B Jan 24, 2020
FY2018 Dec 31, 2016 $59.39B Feb 1, 2019

Revenue (Net Sales)

Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.

Fiscal Year Period End Value Filed
FY2017 Dec 30, 2017 $62.76B Feb 16, 2018
FY2017 Dec 31, 2016 $59.39B Feb 16, 2018
FY2017 Dec 26, 2015 $55.36B Feb 16, 2018
FY2016 Dec 27, 2014 $55.87B Feb 17, 2017
FY2015 Dec 28, 2013 $52.71B Feb 12, 2016
FY2014 Dec 29, 2012 $53.34B Feb 13, 2015
FY2013 Dec 31, 2011 $54.00B Feb 14, 2014
FY2012 Dec 25, 2010 $43.62B Feb 19, 2013
FY2011 Dec 26, 2009 $35.13B Feb 23, 2012
FY2010 Dec 27, 2008 $37.59B Feb 18, 2011

Gross Profit

Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.

Fiscal Year Period End Value Filed
FY2025 Dec 27, 2025 $18.38B Jan 23, 2026
FY2025 Dec 28, 2024 $17.35B Jan 23, 2026
FY2025 Dec 30, 2023 $21.71B Jan 23, 2026
FY2024 Dec 31, 2022 $26.87B Jan 31, 2025
FY2023 Dec 25, 2021 $43.82B Jan 26, 2024
FY2022 Dec 26, 2020 $43.61B Jan 27, 2023
FY2021 Dec 28, 2019 $42.14B Jan 27, 2022
FY2020 Dec 29, 2018 $43.74B Jan 22, 2021
FY2019 Dec 30, 2017 $39.10B Jan 24, 2020
FY2018 Dec 31, 2016 $36.23B Feb 1, 2019

Net Income

The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.

Fiscal Year Period End Value Filed
FY2025 Dec 27, 2025 ($267.00M) Jan 23, 2026
FY2025 Dec 28, 2024 ($18.76B) Jan 23, 2026
FY2025 Dec 30, 2023 $1.69B Jan 23, 2026
FY2024 Dec 31, 2022 $8.01B Jan 31, 2025
FY2023 Dec 25, 2021 $19.87B Jan 26, 2024
FY2022 Dec 26, 2020 $20.90B Jan 27, 2023
FY2021 Dec 28, 2019 $21.05B Jan 27, 2022
FY2020 Dec 29, 2018 $21.05B Jan 22, 2021
FY2019 Dec 30, 2017 $9.60B Jan 24, 2020
FY2018 Dec 31, 2016 $10.32B Feb 1, 2019

Operating Income

Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.

Fiscal Year Period End Value Filed
FY2025 Dec 27, 2025 ($2.21B) Jan 23, 2026
FY2025 Dec 28, 2024 ($11.68B) Jan 23, 2026
FY2025 Dec 30, 2023 $93.00M Jan 23, 2026
FY2024 Dec 31, 2022 $2.33B Jan 31, 2025
FY2023 Dec 25, 2021 $19.46B Jan 26, 2024
FY2022 Dec 26, 2020 $23.68B Jan 27, 2023
FY2021 Dec 28, 2019 $22.04B Jan 27, 2022
FY2020 Dec 29, 2018 $23.32B Jan 22, 2021
FY2019 Dec 30, 2017 $18.05B Jan 24, 2020
FY2018 Dec 31, 2016 $13.13B Feb 1, 2019

R&D Expense

Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.

Fiscal Year Period End Value Filed
FY2025 Dec 27, 2025 $13.77B Jan 23, 2026
FY2025 Dec 28, 2024 $16.55B Jan 23, 2026
FY2025 Dec 30, 2023 $16.05B Jan 23, 2026
FY2024 Dec 31, 2022 $17.53B Jan 31, 2025
FY2023 Dec 25, 2021 $15.19B Jan 26, 2024
FY2022 Dec 26, 2020 $13.56B Jan 27, 2023
FY2021 Dec 28, 2019 $13.36B Jan 27, 2022
FY2020 Dec 29, 2018 $13.54B Jan 22, 2021
FY2019 Dec 30, 2017 $13.04B Jan 24, 2020
FY2018 Dec 31, 2016 $12.69B Feb 1, 2019

SG&A Expense

Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.

Fiscal Year Period End Value Filed
FY2025 Dec 27, 2025 $4.62B Jan 23, 2026
FY2025 Dec 28, 2024 $5.51B Jan 23, 2026
FY2025 Dec 30, 2023 $5.63B Jan 23, 2026
FY2024 Dec 31, 2022 $7.00B Jan 31, 2025
FY2023 Dec 25, 2021 $6.54B Jan 26, 2024
FY2022 Dec 26, 2020 $6.18B Jan 27, 2023
FY2021 Dec 28, 2019 $6.35B Jan 27, 2022
FY2020 Dec 29, 2018 $6.95B Jan 22, 2021
FY2019 Dec 30, 2017 $7.45B Jan 24, 2020
FY2018 Dec 31, 2016 $8.38B Feb 1, 2019

Operating Cash Flow

Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.

Fiscal Year Period End Value Filed
FY2025 Dec 27, 2025 $9.70B Jan 23, 2026
FY2025 Dec 28, 2024 $8.29B Jan 23, 2026
FY2025 Dec 30, 2023 $11.47B Jan 23, 2026
FY2024 Dec 31, 2022 $15.43B Jan 31, 2025
FY2023 Dec 25, 2021 $29.46B Jan 26, 2024
FY2022 Dec 26, 2020 $35.86B Jan 27, 2023
FY2021 Dec 28, 2019 $33.15B Jan 27, 2022
FY2020 Dec 29, 2018 $29.43B Jan 22, 2021
FY2019 Dec 30, 2017 $22.11B Jan 24, 2020
FY2012 Dec 29, 2012 $18.88B Feb 19, 2013

Capital Expenditures (Capex)

Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.

Fiscal Year Period End Value Filed
FY2025 Dec 27, 2025 $14.65B Jan 23, 2026
FY2025 Dec 28, 2024 $23.94B Jan 23, 2026
FY2025 Dec 30, 2023 $25.75B Jan 23, 2026
FY2024 Dec 31, 2022 $24.84B Jan 31, 2025
FY2023 Dec 25, 2021 $18.73B Jan 26, 2024
FY2022 Dec 26, 2020 $14.26B Jan 27, 2023
FY2021 Dec 28, 2019 $16.21B Jan 27, 2022
FY2020 Dec 29, 2018 $15.18B Jan 22, 2021
FY2019 Dec 30, 2017 $11.78B Jan 24, 2020
FY2018 Dec 31, 2016 $9.63B Feb 1, 2019

Total Assets

The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.

Fiscal Year Period End Value Filed
FY2025 Dec 27, 2025 $211.43B Jan 23, 2026
FY2025 Dec 28, 2024 $196.49B Jan 23, 2026
FY2024 Dec 30, 2023 $191.57B Jan 31, 2025
FY2023 Dec 31, 2022 $182.10B Jan 26, 2024
FY2022 Dec 25, 2021 $168.41B Jan 27, 2023
FY2021 Dec 26, 2020 $153.09B Jan 27, 2022
FY2020 Dec 28, 2019 $136.52B Jan 22, 2021
FY2019 Dec 29, 2018 $127.96B Jan 24, 2020
FY2018 Dec 30, 2017 $123.25B Feb 1, 2019
FY2017 Dec 31, 2016 $113.33B Feb 16, 2018

Stockholders Equity

The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.

Fiscal Year Period End Value Filed
FY2025 Dec 27, 2025 $114.28B Jan 23, 2026
FY2025 Dec 28, 2024 $99.27B Jan 23, 2026
FY2024 Dec 30, 2023 $105.59B Jan 31, 2025
FY2023 Dec 31, 2022 $101.42B Jan 26, 2024
FY2022 Dec 25, 2021 $95.39B Jan 27, 2023
FY2021 Dec 26, 2020 $81.04B Jan 27, 2022
FY2021 Dec 28, 2019 $77.50B Jan 27, 2022
FY2021 Dec 29, 2018 $74.56B Jan 27, 2022
FY2020 Dec 30, 2017 $69.65B Jan 22, 2021
FY2019 Dec 31, 2016 $66.23B Jan 24, 2020

Goodwill

An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.

Fiscal Year Period End Value Filed
FY2025 Dec 27, 2025 $23.91B Jan 23, 2026
FY2025 Dec 28, 2024 $24.69B Jan 23, 2026
FY2025 Dec 30, 2023 $27.59B Jan 23, 2026
FY2024 Dec 31, 2022 $27.59B Jan 31, 2025
FY2023 Dec 25, 2021 $26.96B Jan 26, 2024
FY2022 Dec 26, 2020 $26.97B Jan 27, 2023
FY2021 Dec 28, 2019 $26.28B Jan 27, 2022
FY2020 Dec 29, 2018 $24.51B Jan 22, 2021
FY2019 Dec 30, 2017 $24.39B Jan 24, 2020
FY2018 Dec 31, 2016 $14.10B Feb 1, 2019

Retained Earnings

Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.

Fiscal Year Period End Value Filed
FY2025 Dec 27, 2025 $48.98B Jan 23, 2026
FY2025 Dec 28, 2024 $49.03B Jan 23, 2026
FY2024 Dec 30, 2023 $69.16B Jan 31, 2025
FY2023 Dec 31, 2022 $70.41B Jan 26, 2024
FY2022 Dec 25, 2021 $68.27B Jan 27, 2023
FY2021 Dec 26, 2020 $56.23B Jan 27, 2022
FY2020 Dec 28, 2019 $53.52B Jan 22, 2021
FY2019 Dec 29, 2018 $50.17B Jan 24, 2020
FY2018 Dec 30, 2017 $42.08B Feb 1, 2019
FY2017 Dec 31, 2016 $40.75B Feb 16, 2018

Cash & Equivalents

Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.

Fiscal Year Period End Value Filed
FY2025 Dec 27, 2025 $14.27B Jan 23, 2026
FY2025 Dec 28, 2024 $8.25B Jan 23, 2026
FY2018 Dec 29, 2018 $3.02B Feb 1, 2019
FY2018 Dec 30, 2017 $3.43B Feb 1, 2019
FY2018 Dec 31, 2016 $5.56B Feb 1, 2019
FY2018 Dec 26, 2015 $15.31B Feb 1, 2019
FY2017 Dec 27, 2014 $2.56B Feb 16, 2018
FY2016 Dec 28, 2013 $5.67B Feb 17, 2017
FY2015 Dec 29, 2012 $8.48B Feb 12, 2016
FY2014 Dec 31, 2011 $5.07B Feb 13, 2015

Long-Term Debt

Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.

Fiscal Year Period End Value Filed
FY2025 Dec 27, 2025 $46.59B Jan 23, 2026
FY2025 Dec 28, 2024 $50.01B Jan 23, 2026
FY2024 Dec 30, 2023 $49.27B Jan 31, 2025
FY2023 Dec 31, 2022 $38.11B Jan 26, 2024
FY2022 Dec 25, 2021 $38.10B Jan 27, 2023
FY2021 Dec 26, 2020 $36.40B Jan 27, 2022
FY2020 Dec 28, 2019 $29.00B Jan 22, 2021
FY2019 Dec 29, 2018 $25.86B Jan 24, 2020
FY2018 Dec 30, 2017 $26.78B Feb 1, 2019
FY2017 Dec 31, 2016 $25.26B Feb 16, 2018

EPS (Basic)

Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.

Fiscal Year Period End Value Filed
FY2025 Dec 27, 2025 0 Jan 23, 2026
FY2025 Dec 28, 2024 (4) Jan 23, 2026
FY2025 Dec 30, 2023 0 Jan 23, 2026
FY2024 Dec 31, 2022 1 Jan 31, 2025
FY2023 Dec 25, 2021 4 Jan 26, 2024
FY2022 Dec 26, 2020 4 Jan 27, 2023
FY2021 Dec 28, 2019 4 Jan 27, 2022
FY2020 Dec 29, 2018 4 Jan 22, 2021
FY2019 Dec 30, 2017 2 Jan 24, 2020
FY2018 Dec 31, 2016 2 Feb 1, 2019

EPS (Diluted)

Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.

Fiscal Year Period End Value Filed
FY2025 Dec 27, 2025 0 Jan 23, 2026
FY2025 Dec 28, 2024 (4) Jan 23, 2026
FY2025 Dec 30, 2023 0 Jan 23, 2026
FY2024 Dec 31, 2022 1 Jan 31, 2025
FY2023 Dec 25, 2021 4 Jan 26, 2024
FY2022 Dec 26, 2020 4 Jan 27, 2023
FY2021 Dec 28, 2019 4 Jan 27, 2022
FY2020 Dec 29, 2018 4 Jan 22, 2021
FY2019 Dec 30, 2017 1 Jan 24, 2020
FY2018 Dec 31, 2016 2 Feb 1, 2019

Shares Outstanding

Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.

Fiscal Year Period End Value Filed
FY2025 Dec 27, 2025 4.99B Jan 23, 2026
FY2025 Dec 28, 2024 4.33B Jan 23, 2026
FY2024 Dec 30, 2023 4.23B Jan 31, 2025
FY2023 Dec 31, 2022 4.14B Jan 26, 2024
FY2022 Dec 25, 2021 4.07B Jan 27, 2023
FY2021 Dec 26, 2020 4.06B Jan 27, 2022
FY2020 Dec 28, 2019 4.29B Jan 22, 2021
FY2019 Dec 29, 2018 4.52B Jan 24, 2020
FY2018 Dec 30, 2017 4.69B Feb 1, 2019
FY2017 Dec 31, 2016 4.73B Feb 16, 2018

Dividends Paid

Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.

Fiscal Year Period End Value Filed
FY2025 Dec 27, 2025 $0 Jan 23, 2026
FY2025 Dec 28, 2024 $1.60B Jan 23, 2026
FY2025 Dec 30, 2023 $3.09B Jan 23, 2026
FY2024 Dec 31, 2022 $6.00B Jan 31, 2025
FY2023 Dec 25, 2021 $5.64B Jan 26, 2024
FY2022 Dec 26, 2020 $5.57B Jan 27, 2023
FY2021 Dec 28, 2019 $5.58B Jan 27, 2022
FY2020 Dec 29, 2018 $5.54B Jan 22, 2021
FY2019 Dec 30, 2017 $5.07B Jan 24, 2020
FY2018 Dec 31, 2016 $4.93B Feb 1, 2019